Close Menu

Northwestern University

Men with metastatic castration-resistant prostate cancer who had mutations in genes like BRCA1 and BRCA2 benefited from treatment with olaparib.

Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.